# Effect of Different Dosing Regimens of Tadalafil or Tamsulosin Combined With 5α-Reductase Inhibitors on Urinary and Sexual Outcomes in Benign Prostatic Hyperplasia

> **NCT07715448** · PHASE4 · COMPLETED · sponsor: **Beni-Suef University** · enrollment: 240 (actual)

## Conditions studied

- Benign Prostatic Hyperplasia
- Lower Urinary Tract Symptoms
- Erectile Dysfunction

## Interventions

- **DRUG:** Tamsulosin
- **DRUG:** Tadalafil
- **DRUG:** 5-Alpha Reductase Inhibitor

## Key facts

- **NCT ID:** NCT07715448
- **Lead sponsor:** Beni-Suef University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** 2026-01-01
- **Final completion:** 2026-01-01
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2026-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07715448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07715448, "Effect of Different Dosing Regimens of Tadalafil or Tamsulosin Combined With 5α-Reductase Inhibitors on Urinary and Sexual Outcomes in Benign Prostatic Hyperplasia". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07715448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*